Myelopeptide-2, originally extracted from porcine bone marrow cell culture supernatants, can restore the mitogen reactivity, interleukin-2 (IL-2) synthesis levels and levels of human T lymphocytes under conditional inhibition of HL-60 leukemia cells or measles virus. Interleukin-2 receptor (IL-2R) expression levels. Myelopeptide-2 is involved in the regulation of immune homeostasis and has broad application prospects in anti-tumor and anti-viral research.

Physicochemical Properties

Molecular Formula	C41H57N7O8
Molecular Weight	775.933390378952
Exact Mass	775.426
CAS #	137833-31-9
PubChem CID	9810873
Appearance	Typically exists as solid at room temperature
LogP	1.9
Hydrogen Bond Donor Count	8
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	18
Heavy Atom Count	56
Complexity	1370
Defined Atom Stereocenter Count	6
SMILES	CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N
InChi Key	ITQOCODEBWMEKP-LXOXETEGSA-N
InChi Code	InChI=1S/C41H57N7O8/c1-22(2)18-29(42)36(50)46-35(24(5)6)39(53)47-34(23(3)4)38(52)44-31(19-25-13-15-27(49)16-14-25)40(54)48-17-9-12-33(48)37(51)45-32(41(55)56)20-26-21-43-30-11-8-7-10-28(26)30/h7-8,10-11,13-16,21-24,29,31-35,43,49H,9,12,17-20,42H2,1-6H3,(H,44,52)(H,45,51)(H,46,50)(H,47,53)(H,55,56)/t29-,31-,32-,33-,34-,35-/m0/s1
Chemical Name	(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoic acid
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	IL-2
ln Vitro	Human peripheral blood T cells stimulated to proliferate by phytohemagglutinin (PHA, 2.5 mg/mL) are restored by myelopeptide-2 (1 ng/mL-0.1 mg/mL; 72 h)[1]. Human T cells injured by the measles virus or HL-60 exhibit an increase in the level of reduced IL-2 production in response to myelopeptide-2 (0.1 mg/mL and 1 mg/mL; 1-3 d)[1].
ln Vivo	In mice receiving short-term treatment, myelopeptide-2 (10 μg/kg; injection; for 20–50 weeks) reduces the number of spontaneous and urethane-induced lung tumors and delays the emergence of urethane-induced tumors[2].
Animal Protocol	Animal/Disease Models: Male balb/c (Bagg ALBino) mouse (3-month-old) with spontaneous lung tumors[2] Doses: 10 μg/kg; accompanied with 0.5 mg/kg Urethane or not Route of Administration: Routine injection; (1) 1 injection of MP-2 and after 7 days 3 injections of MP-2 every other day, (2) or alternating with injections of urethane (4 injections of MP-2; 3 injections of urethane+4 injections of MP-2); (3) 3 injections of MP-2 every other day or (4) alternating with injections of urethane and after 3 weeks 2 injections of MP-2 monthly with one-week interval, a total of 22 injections (25 injections of MP-2; 3 injections of urethane+ 25 injections of MP-2). For 20-50 weeks. Experimental Results: Dramatically lowered the incidence of urethane-induced lung adenomas in animals receiving 4 injections of MP-2 compared to the group receiving urethane alone or in combination with 25 injections of MP -2.
References	[1]. Mikhailova AA, et al. Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. J Immunother. 2006 May-Jun;29(3):306-12. [2]. Mikhailova AA, et al. Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice. Bull Exp Biol Med. 2002 Jan;133(1):68-70.

Solubility Data

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.2888 mL	6.4439 mL	12.8878 mL
	5 mM	0.2578 mL	1.2888 mL	2.5776 mL
	10 mM	0.1289 mL	0.6444 mL	1.2888 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.